ClinicalTrials.gg
CompletedNCT00174785ATHENAUpdated Jan 12, 2010Results posted

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

A Phase 3 interventional study of dronedarone (SR33589) and placebo in Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi. Completed at 37 sites in 37 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2010-01-12.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,628
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
Largest of 26
4,628 · median 164
Started
2005
the only one that year
Phase 3
7 of 26
none open now
Registered
1st of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one has the largest enrollment, is the only one that started in 2005, is one of 7 in phase 3, and was the 1st registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).

To assess that dronedarone is well tolerated in this population.

Read the detailed description

This is a prospective, multinational, double-blind, randomized, multi-center, placebo-controlled, parallel-group trial evaluating the effects of dronedarone versus placebo (ratio 1:1) over a minimum treatment duration of 12 months and a mean follow-up duration of 1.75 years (in AF/AFL patients). Patients can be included in the study while in atrial fibrillation/flutter or in sinus rhythm if conversion has occurred either spontaneously or following a procedure such as electrical cardioversion (or overdrive pacing) or administration of an antiarrhythmic drug.After randomization all patients will be followed until the common study end date; the last patient included in the study will be followed for 1 year. Visits will be at baseline, after 7 days, after 14 days, after one month, after three months and then every three months until end of the study. At each visit patients will be asked for the occurrence of hospitalizations or other events since the last visit. The study will be monitored by an independent Data Monitoring Committee (DMC) for safety, tolerability and efficacy.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Flutter

Keywords

  • Mortality, Hospitalization
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patients aged 75 years or older (70 years before protocol amendment 1), or patients aged at least 70 years (any age before protocol amendment 1) with one or more of the following risk factors at baseline:

    • Hypertension (taking antihypertensive drugs of at least two different classes)
    • Diabetes
    • Prior cerebrovascular accident (stroke or ) or systemic embolism
    • Left atrium diameter greater than or equal to 50 mm by echocardiography
    • less than 0.40 by 2D-echocardiography (two-dimensional echocardiography)
  • 2. Availability of one (ECG) within the last 6 months, showing that the patient was or is in AF/AFL
  • 3. Availability of one ECG within the last 6 months, showing that the patient was or is in sinus rhythm

Exclusion criteria

Exclusion Criteria:

General criteria:

  • 1. Refusal or inability to give to participate in the study
  • 2. Any non cardiovascular illness or disorder that could preclude participation or severely limit survival including cancer with and organ transplantation requiring immune suppression
  • 3. Pregnant women (pregnancy test must be negative) or women of not on adequate : only women with a highly effective method of contraception [oral contraception or intra-uterine device (IUD)] or sterile can be randomized.
  • 4. Breastfeeding women
  • 5. Previous (2 preceding months) or current participation in another clinical trial with an drug (under development) or with an investigational device
  • 6. Previous participation in this trial

Criteria Related to a cardiac condition:

  • 7. Patients in permanent atrial fibrillation
  • 8. Patients in unstable hemodynamic condition such as acute pulmonary edema within 12 hours prior to start of study medication; cardiogenic shock; treatment with intra-venous pressor agents; patients on respirator; congestive heart failure of stage IV (New York Heart Association classification) within the last 4 weeks; uncorrected, hemodynamically significant primary obstructive valvular disease; hemodynamically significant obstructive cardiomyopathy; a cardiac operation or revascularization procedure within 4 weeks preceding randomization
  • 9. Planned major non-cardiac or cardiac surgery or procedures including surgery for valvular heart disease, coronary artery bypass graft (CABG) , percutaneous coronary intervention (PCI) , or on urgent cardiac transplantation list
  • 10. Acute myocarditis or constrictive pericarditis
  • 11. Bradycardia \< 50 bpm and/or PR-interval > 0.28 sec on the last 12-lead
  • 12. Significant sinus node disease (documented pause of 3 seconds or more) or 2nd or 3rd degree atrioventricular block (AV-block) unless treated with a pacemaker

Criteria Related to Concomitant Medications:

  • 13. Need of a concomitant medication that is prohibited in this trial, including the requirement for Vaughan Williams Class I and III anti-arrhythmic drugs, that would preclude the use of study drug during the planned study period

Criteria Related to Laboratory Abnormalities:

  • 14. Plasma potassium \< 3.5 mmol/l (as anti-arrhythmic drugs can be arrhythmogenic in patients with hypokalemia, this must be corrected prior to randomization)
  • 15. A calculated (GFR) at baseline \<10 ml/min using the Cockroft Gault formula
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4,628 participants (actual)

Study arms

  • Experimental
    Dronedarone 400mg bid

    Dronedarone 400mg tablets twice daily (bid)

    Drug: dronedarone (SR33589)

  • Placebo comparator
    Placebo

    matching placebo tablets

    Drug: placebo

Interventions

  • oral administration (tablets)

    Also known as: Multaq®

  • Drugplacebo

    oral administration (tablets)

06

What researchers measure

Primary outcomes

  1. First Hospitalization for Cardiovascular Reason or Death From Any Cause

    The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years

Secondary outcomes

  1. Death From Any Cause

    The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years

  2. First Hospitalization for Cardiovascular Reason

    The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years

  3. Cardiovascular Death

    The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years

Other outcomes

  1. Adjudicated Cardiovascular Death

    The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years

07

Results

Posted Dec 23, 2009

Participant flow

Enrollment of patients started on June 29, 2005 and was completed on December 30, 2006. The study was conducted at 551 centers in 37 countries. The common study end date ensuring a minimum planned follow-up of one year was December 30th, 2007.

Participant flow — Overall Study
MilestoneDronedarone 400mg BidPlacebo
Started23012327
Completed16051611
Not completed696716
Withdrew: Adverse event293191
Withdrew: Protocol violation1414
Withdrew: Withdrawal by subject173175
Withdrew: Atrial fibrillation/flutter recurrence110167
Withdrew: Prohibited antiarrhythmic medication3988
Withdrew: Other prohibited medication53
Withdrew: Family request68
Withdrew: Not pre-specified/not coded5670

Outcome measures

PrimaryFirst Hospitalization for Cardiovascular Reason or Death From Any Cause

The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum follow-up duration: 1 year ; maximum: 2.5 years
Reported as:
Number · participants
First Hospitalization for Cardiovascular Reason or Death From Any Cause
participantsDronedarone 400mg BidPlacebo
First Hospitalization for Cardiovascular Reason or Death From Any Cause734917
Statistical analysis
  • Dronedarone 400mg Bid vs Placebo · Log Rank · p = <0.0001 (Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 0.76 · 95% CI 0.69 to 0.84The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of first hospitalization for cardiovascular reason or death for the dronedarone group compared with the placebo group.
SecondaryDeath From Any Cause

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum follow-up duration: 1 year ; maximum: 2.5 years
Reported as:
Number · participants
Death From Any Cause
participantsDronedarone 400mg BidPlacebo
Death From Any Cause116139
Statistical analysis
  • Dronedarone 400mg Bid vs Placebo · Log Rank · p = 0.18 (Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. Hierarchical procedure applied to secondary efficacy endpoints testing to protect the global type I error.) · Hazard ratio (hr): 0.84 · 95% CI 0.66 to 1.08The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of death from any cause for the dronedarone group compared with the placebo group.
SecondaryFirst Hospitalization for Cardiovascular Reason

The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum follow-up duration: 1 year ; maximum: 2.5 years
Reported as:
Number · participants
First Hospitalization for Cardiovascular Reason
participantsDronedarone 400mg BidPlacebo
First Hospitalization for Cardiovascular Reason675859
Statistical analysis
  • Dronedarone 400mg Bid vs Placebo · Log Rank · p = <0.0001 (Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. Hierarchical procedure applied to secondary efficacy endpoints testing to protect the global type I error.) · Hazard ratio (hr): 0.74 · 95% CI 0.67 to 0.82The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of first hospitalization for cardiovascular reason for the dronedarone group compared with the placebo group.
SecondaryCardiovascular Death

The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum follow-up duration: 1 year ; maximum: 2.5 years
Reported as:
Number · participants
Cardiovascular Death
participantsDronedarone 400mg BidPlacebo
Cardiovascular Death6594
Statistical analysis
  • Dronedarone 400mg Bid vs Placebo · Log Rank · p = 0.025 (Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. Hierarchical procedure applied to secondary efficacy endpoints testing to protect the global type I error.) · Hazard ratio (hr): 0.70 · 95% CI 0.51 to 0.96The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of cardiovascular death for the dronedarone group compared with the placebo group.
Other pre-specifiedAdjudicated Cardiovascular Death

The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum follow-up duration: 1 year ; maximum: 2.5 years
Reported as:
Number · participants
Adjudicated Cardiovascular Death
participantsDronedarone 400mg BidPlacebo
Adjudicated Cardiovascular Death6390
Statistical analysis
  • Dronedarone 400mg Bid vs Placebo · Log Rank · p = 0.03 (Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The comparison was performed at the 5% level using a 2-sided Log rank) · Hazard ratio (hr): 0.71 · 95% CI 0.51 to 0.98The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of adjudicated cardiovascular death for the dronedarone group compared with the placebo group.

Adverse events

Collected over In both treatment groups, the median duration of exposure was about 18 months, with a maximum of 30 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dronedarone 400mg Bid—456/2,291 (19.9%)1,584/2,291 (69.1%)
Placebo—489/2,313 (21.1%)1,527/2,313 (66%)
Most frequent serious events
Showing 10 of 549
Most frequent serious events
EventDronedarone 400mg BidPlacebo
PneumoniaInfections and infestations32/229145/2313
OsteoarthritisMusculoskeletal and connective tissue disorders15/229121/2313
FallInjury, poisoning and procedural complications20/229120/2313
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders13/229119/2313
Renal failure acuteRenal and urinary disorders14/22914/2313
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/229111/2313
Urinary tract infectionInfections and infestations6/229110/2313
DehydrationMetabolism and nutrition disorders4/229110/2313
Benign prostatic hyperplasiaReproductive system and breast disorders8/229110/2313
HaematuriaRenal and urinary disorders7/22917/2313
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDronedarone 400mg BidPlacebo
Any Gastrointestinal disordersGastrointestinal disorders573/2291478/2313
Any infections and infestationsInfections and infestations508/2291533/2313
Any general disorders and administration site conditionsGeneral disorders397/2291348/2313
Any musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders364/2291376/2313
Any nervous system disordersNervous system disorders362/2291365/2313
Any respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders315/2291318/2313
Any investigation disordersInvestigations298/2291199/2313
Any cardiac disordersCardiac disorders251/2291213/2313
Any skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders235/2291174/2313
DiarrhoeaGastrointestinal disorders222/2291142/2313

Baseline characteristics

Age, Customized
Age, Customized(participants)Dronedarone 400mg BidPlaceboTotal
18 to < 65 years431442873
65 to < 75 years9239071830
>= 75 years9479781925
Age Continuous
Age Continuous(years)Dronedarone 400mg BidPlaceboTotal
Mean71.6 ± 8.971.7 ± 9.071.6 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Dronedarone 400mg BidPlaceboTotal
Female113110382169
Male117012892459
08

Study locations

37 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    New South Wales, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Santiago, Chile
  • Sanofi-Aventis Administrative Office
    Shangaï, China
  • Sanofi-Aventis Administrative Office
    Prague, Czechia
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Causeway Bay, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Netanya, Israel
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    México, Mexico
  • Sanofi-Aventis Administrative Office
    Casablanca, Morocco
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Macquarie Park, New Zealand
  • Sanofi-Aventis Administrative Office
    Lysaker, Norway
  • Sanofi-Aventis Administrative Office
    Makati City, Philippines
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Moscow, Russia
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Administrative Office
    Seoul, South Korea
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Bangkok, Thailand
  • Sanofi-Aventis Administrative Office
    Mégrine, Tunisia
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey (Türkiye)
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol. 2008 Jan;19(1):69-73. doi: 10.1111/j.1540-8167.2007.01016.x. Epub 2007 Nov 21. PubMed 18031520 ↗
  • Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. PubMed 19213680 ↗
  • Vamos M, Vagvolgyi A, McKindley DS, Hohnloser SH. Efficacy and Safety of Dronedarone in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial. J Cardiovasc Electrophysiol. 2026 May;37(5):969-979. doi: 10.1111/jce.70322. Epub 2026 Mar 22. PubMed 41865291 ↗
  • Kirchhof P, Camm AJ, Crijns HJGM, Piccini JP, Torp-Pedersen C, McKindley DS, Wieloch M, Hohnloser SH. Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria. Europace. 2025 Mar 28;27(4):euaf080. doi: 10.1093/europace/euaf080. PubMed 40295782 ↗
  • Handelsman Y, Bunch TJ, Rodbard HW, Steinberg BA, Thind M, Bigot G, Konigsberg L, Wieloch M, Kowey PR. Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. J Diabetes Complications. 2022 Jul;36(7):108227. doi: 10.1016/j.jdiacomp.2022.108227. Epub 2022 Jun 8. PubMed 35717354 ↗
  • Vamos M, Oldgren J, Nam GB, Lip GYH, Calkins H, Zhu J, Ueng KC, Ludwigs U, Wieloch M, Stewart J, Hohnloser SH. Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. Eur Heart J Cardiovasc Pharmacother. 2022 Jun 8;8(4):363-371. doi: 10.1093/ehjcvp/pvab090. PubMed 34958366 ↗
  • Akerborg O, Nilsson J, Bascle S, Lindgren P, Reynolds M. Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. Clin Ther. 2012 Aug;34(8):1788-802. doi: 10.1016/j.clinthera.2012.06.007. Epub 2012 Jul 6. PubMed 22770643 ↗
  • Torp-Pedersen C, Crijns HJ, Gaudin C, Page RL, Connolly SJ, Hohnloser SH; ATHENA Investigators. Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace. 2011 Aug;13(8):1118-26. doi: 10.1093/europace/eur102. Epub 2011 May 15. PubMed 21576129 ↗
  • Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Pedersen C, Hohnloser SH; ATHENA Investigators. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011 Apr 1;107(7):1019-22. doi: 10.1016/j.amjcard.2010.11.028. Epub 2011 Feb 4. PubMed 21296333 ↗
  • Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J. 2010 Jul;31(14):1717-21. doi: 10.1093/eurheartj/ehq113. Epub 2010 Apr 30. PubMed 20436046 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
Start
Jun 2005
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Dec 23, 2009
Last update
Jan 12, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174785
Lead sponsor
Sanofi
First posted
Sep 15, 2005
Start date
Jun 2005
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Dec 23, 2009
Last update
Jan 12, 2010

Study contacts

International Clinical Development
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion